Catalyst Starts Enrolling Patients with Methamphetamine Addiction

Patients who are addicted to methamphetamine are enrolling in Catalyst Pharmaceuticals’ Phase II clinical trial using CPP-109.

CPP-109 is an orally administered, small molecule drug that inhibits psychostimulant-induced dopamine release. It is the company’s version of vigabatrin, an anticonvulsant that has shown promise in treating substance dependency.

The randomized, double-blind, placebo-controlled, multicenter trial will evaluate the safety and efficacy of the drug in 180 patients at 15 addiction treatment centers in the U.S. Patients will be treated for a period of 12 weeks with an additional 12 weeks of follow-up, Catalyst said.